BMRN
Biomarin Pharmaceutical Inc
NASDAQ: BMRN · HEALTHCARE · BIOTECHNOLOGY
$54.21
+1.71% today
Updated 2026-04-29
Market cap
$10.48B
P/E ratio
30.12
P/S ratio
3.25x
EPS (TTM)
$1.80
Dividend yield
—
52W range
$51 – $66
Volume
2.0M
Biomarin Pharmaceutical Inc (BMRN) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $463.44M | $815.28M | $906.70M | $917.16M | $1.26B | $1.31B | $1.57B | $2.24B | $2.49B | $3.73B | $4.02B | $4.63B | $4.43B | $4.69B | $5.85B | $6.00B | $6.38B | $6.84B | $6.99B | — |
| Cash & equivalents | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current assets | $334.22M | $644.30M | $737.70M | $467.73M | $504.26M | $469.80M | $743.46M | $1.14B | $1.43B | $1.09B | $1.42B | $2.21B | $2.06B | $1.94B | $2.34B | $2.27B | $2.75B | $2.96B | $3.23B | — |
| Total liabilities | $345.63M | $627.55M | $630.02M | $594.98M | $545.37M | $532.66M | $552.58M | $903.02M | $962.56M | $1.33B | $1.26B | $1.82B | $1.46B | $1.57B | $1.74B | $1.73B | $1.77B | $1.89B | $1.33B | — |
| Current liabilities | $46.05M | $61.54M | $130.08M | $78.15M | $83.84M | $94.13M | $170.43M | $183.27M | $235.74M | $445.46M | $439.31M | $816.52M | $523.24M | $932.50M | $492.55M | $539.82M | $588.88M | $1.18B | $606.99M | — |
| Long-term debt | $292.49M | $563.93M | $497.35M | $497.17M | $377.52M | $348.33M | $324.86M | $655.57M | $657.98M | $662.29M | $660.76M | $813.52M | $830.42M | $486.24M | $1.08B | $1.08B | $1.08B | $593.10M | $595.14M | — |
| Shareholder equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Retained earnings | $-591.62M | $-607.43M | $-576.60M | $-577.08M | $-371.26M | $-425.10M | $-539.45M | $-715.80M | $-849.77M | $-1.02B | $-1.52B | $-1.64B | $-1.69B | $-1.72B | $-861.61M | $-925.69M | $-789.20M | $-621.55M | $-194.69M | — |
| Accounts receivable | $14.67M | $16.98M | $54.30M | $80.62M | $86.58M | $115.64M | $109.07M | $129.34M | $144.47M | $164.96M | $215.28M | $261.37M | $342.63M | $377.40M | $448.35M | $373.40M | $461.32M | $633.70M | $660.53M | — |
| Inventory | $25.07M | $32.45M | $73.16M | $78.66M | $109.70M | $130.12M | $128.69M | $162.60M | $199.45M | $271.68M | $355.13M | $475.77M | $530.87M | $680.27M | $698.55M | $776.67M | $894.08M | $1.11B | $1.23B | — |
| Goodwill | $21.26M | $21.26M | $21.26M | $23.72M | $53.36M | $51.54M | $51.54M | $54.26M | $54.26M | $197.04M | $197.04M | $197.04M | $197.04M | $197.04M | $196.20M | $196.20M | $196.20M | $196.20M | $196.20M | — |